Hardman, C., Chen, W., Luo, J., Batty, P., Chen, Y., Nahler, J., . . . Ogg, G. (2019). Fevipiprant, a selective prostaglandin D2 receptor 2 antagonist, inhibits human group 2 innate lymphoid cell aggregation and function. Elsevier.
Chicago Style (17th ed.) CitationHardman, C., et al. Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Inhibits Human Group 2 Innate Lymphoid Cell Aggregation and Function. Elsevier, 2019.
MLA引文Hardman, C., et al. Fevipiprant, a Selective Prostaglandin D2 Receptor 2 Antagonist, Inhibits Human Group 2 Innate Lymphoid Cell Aggregation and Function. Elsevier, 2019.
警告：這些引文格式不一定是100％准確.